Investors Overview

Company Profile

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B.

Recent/Upcoming Events
Oct 03, 2023 at 4:30 PM CEST

Oral Presentation: Phase 2, Randomized, Placebo-controlled Trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in subjects with overweight or obesity: a 24-week interim analysis (Session OP 10, Oral Presentation 60)

Presenter: Louis J. Aronne, M.D., Founder and Director, Center for Weight Management at Weill-Cornell Medical Center

btn Events


Investor Contact

Richard Eisenstadt
Chief Financial Officer



Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail